 Agencies
NEW DELHI, Mar 31: In a recent academic colloquium organized by the Haemophilia & Health Collective of North India (HHCN) in Dehradun, experts convened to address the evolving landscape of Haemophilia care. The colloquium, themed "Changing Landscape of Haemophilia Care: Unmet Needs & Solutions," focused on enhancing clinical care and patient adherence amidst the availability of new drug products.
Distinguished experts from across North India participated in the event, including Dr. Naresh Gupta, Chairperson of HHCN, and esteemed professionals from various renowned institutions such as LNJP Hospital, AIIMS New Delhi, and PGIMS Rohtak, among others.
Dr. Gupta delivered a welcome address, setting the tone for discussions by highlighting the objectives of the meeting and shedding light on emerging therapies for Haemophilia care. Dr. Tulika Seth from AIIMS Delhi provided detailed insights into advances in managing Haemophilia A & B, while Dr. Sunita Aggarwal discussed unmet needs within the present standard of care.
A workshop followed, focusing on newly developed drug products undergoing final trials. Particularly, attention was drawn to the anti-Tissue Factor Pathway Inhibitor (anti-TFPI), categorized under haemostatic rebalancing therapies (Non-factor therapy, NFT), which showed promise in both types of Haemophilia. Experts were briefed on the potential of pen devices for self-administration, enhancing convenience and accessibility for patients.
Dr. K.K. Kaul emphasized the importance of scientifically defining optimal dose schedules, especially for anti-TFPI, based on laboratory monitoring and clinical outcomes. He underscored the potential of pen devices as a crucial unmet need, offering ease of storage, self-infusion capability, and immediate accessibility during bleeding episodes.
Moreover, Dr. Kaul shared insights into ongoing gene therapy trials at CMC Vellore, hinting at the possibility of a cure for Haemophilia in the near future.
The colloquium concluded with a sense of optimism, as experts and stakeholders alike envision a future where advancements in therapies and innovative delivery methods revolutionize Haemophilia care, ultimately improving the quality of life for patients. |
